Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Korean J Intern Med
Auteurs principaux: Oh, Jae Young, Kim, Byung Seok, Lee, Chang Hyeong, Song, Jeong Eun, Lee, Heon Ju, Park, Jung Gil, Hwang, Jae Seok, Chung, Woo Jin, Jang, Byoung Kuk, Kweon, Young Oh, Tak, Won Young, Park, Soo Young, Jang, Se Young, Suh, Jeong Ill, Kwak, Sang Gyu
Format: Artigo
Langue:Inglês
Publié: The Korean Association of Internal Medicine 2019
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6610199/
https://ncbi.nlm.nih.gov/pubmed/29792020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3904/kjim.2017.368
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires